AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

In ADC therapy, payload delivery relies on a selective antibody binding event. Think of ADC therapy as less like a sledgehammer and more like a scalpel. Because antibodies are so large – around ...

These appointments deepen the expertise and experience within the senior leadership as Myricx scales to becomes a clinical stage company, with multiple N-myristoyltransferase inhibitor ADCs (NMTi ...

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate (ADC ... antibody to the therapy’s payload results ...

In addition, Lonza will provide commercial-scale monoclonal antibody (mAb) manufacturing services for a new ADC therapy. Based on an established relationship grounded in quality and delivery, the ...